The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Cell & Gene Therapy manufacturing success rates have historically been challenged by lack of process controls, with failures often undetected until final product release testing. Recently, process automation has improved manufacturing success among clinical programs by reducing human error. However, commercialization of mission-critical manufacturing requires improved processes robustness and additional in-process characterization and control to deliver these needed therapies consistently.
Speaker(s):
Ian
Gaudet,
PhD,
Senior Director and Site Head, San Jose Cell Manufacturing Facility,
Miltenyi Biotec
Credits
Credits: None available.
You must be logged in and own this session in order to
post comments.
